Drugs / Mycobacterium w
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00694798 | Oct 2008 → Jul 2011 | urinary bladder cancer | Cadila Pharnmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00694915 | Aug 2008 → Mar 2014 | bladder transitional cell carcinoma | Cadila Pharnmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00680940 | Jun 2008 → Dec 2010 | non-small cell lung carcinoma | Cadila Pharnmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00525408 | Nov 2007 → Jan 2013 | hormone-resistant prostate carcinoma | Cadila Pharnmaceuticals | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02330432 | Jan 2016 → Oct 2018 | infectious disease with sepsis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04358809 | Jun 2020 → Feb 2021 | COVID-19 | Cadila Pharnmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT04353518 | Jun 2020 → Mar 2021 | COVID-19 | Cadila Pharnmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT00341328 | Mar 2007 → Oct 2011 | tuberculosis | Ministry of Science and Technology, India | Completed | No outcome recorded |
| Phase 3 | NCT00265226 | Mar 2005 → Dec 2010 | tuberculosis | Ministry of Science and Technology, India | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04347174 | Apr → Aug 2020 | COVID-19 | Cadila Pharnmaceuticals | Completed | No outcome recorded |
| — | NCT01424735 | Jul 2006 → Jan 2010 | optic neuritis | Sudhalkar Eye Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mycobacterium w. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00525408 ↗ |
| Known as | Immuvac | “Single daily dose of 0.3 mL of Mw (heat-inactivated Mw \[0.5 × 10\^9\]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days” NCT02330432 ↗ |
| Action | Activate | “Mycobacterium w by its TLR4 agonist activity may help in restoring immunity” NCT02330432 ↗ |
| Modality | Vaccine | “Mycobacterium W Vaccine” NCT00265226 ↗ |
| Route | Other | “received 0.3 mL/d of Mw intradermally” PMID 33852919 ↗ May 2021 |